President & CEO, Antiva Biosciences, Inc.
Gail Maderis is President & CEO of Antiva Biosciences, Inc., a venture-backed biopharmaceutical company pioneering topical therapies to treat the pre-cancerous lesions caused by HPV. Previously, Ms. Maderis led BayBio, Northern California’s life science industry organization. From 2003-2009, she served as President and CEO of Five Prime Therapeutics, a protein discovery company focused on immuno-oncology, which was acquired by Amgen for $1.9 billion. Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis also practiced management and strategy consulting with Bain & Co. She serves on the corporate boards of DURECT (DRRX), Allarity Therapeutics (ALLR), Valitor, Inc. and Antiva Biosciences, as well as on the non-profit boards of BIO (Emerging Company and Health Sections), CLSI, The Termeer Foundation, and the University of California Berkeley Foundation Board of Trustees. She received a BS in business from UC Berkeley, and an MBA from Harvard Business School. In 2018 she was named one of the Bay Area’s most admired CEOs by the San Francisco Business Times.